Search
Paclitaxel Treatment Options in Texas
A collection of 768 research studies where Paclitaxel is the interventional treatment. These studies are located in the Texas, United States. Paclitaxel is used for conditions such as Breast Cancer, Ovarian Cancer and Non-Small Cell Lung Cancer.
625 - 636 of 768
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer
Completed
To demonstrate whether addition of MM-121 to paclitaxel is more effective than treatment with paclitaxel alone, when administered as part of the neoadjuvant treatment in Her2 negative locally advanced operable breast cancer patients.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/30/2016
Locations: Texas Oncology - Amarillo, Amarillo, Texas +13 locations
Conditions: ER Positive, Her2 Negative Breast Cancer Patients, Triple Negative Breast Cancer Patients
A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Completed
The purpose of this Phase 2 study is to investigate whether intravenous administration of REOLYSIN therapeutic reovirus in combination with paclitaxel and carboplatin is effective and safe in the treatment of squamous cell carinoma of the lung.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/29/2016
Locations: Texas Oncology - Arlington South, Arlington, Texas +8 locations
Conditions: Metastatic or Recurrent Squamous Cell Carcinoma of the Lung
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
Completed
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer. In addition, the study will compare the safety and tolerance of IG-001 and nab-paclitaxel during the bioequivalence 2-period crossover portion of the study. The study will also evaluate the long-term safety of IG-001 over repeated cycles, up to 4 additional cycles of administration.
Gender:
FEMALE
Ages:
30 years and above
Trial Updated:
03/23/2016
Locations: Sorrento investigational site, Flower Mound, Texas
Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Study of Abraxane Plus Hormonal Therapy as Initial Treatment of Unresectable or Metastatic Prostate Cancer
Terminated
The purpose of the clinical trial is to assess the clinical benefit as measured by time to tumor progression of Abraxane plus hormonal therapy when applied to previously untreated patients with unresectable or metastatic adenocarcinoma of the prostate, as well as to assess safety and tolerability of the study drug regimen and to evaluate secondary efficacy endpoints such as overall survival and duration of response.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: Baylor College of Medicine - Methodist Hospital, Houston, Texas
Conditions: Prostatic Neoplasms
Efficacy and Safety Study of Xyotax to Treat Prostate Cancer
Completed
The purpose of this study is to determine whether Xyotax, a conjugate of the taxane drug paclitaxel, is effective in the treatment of prostate cancer that is no longer responsive to hormone therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/15/2016
Locations: Baylor College of Medicine -Methodist Hospital, Houston, Texas
Conditions: Prostatic Neoplasms
BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)
Completed
The goal of this study is to find the highest tolerable dose of BAY 43-9006 (sorafenib) and bevacizumab that can be given with paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC). The safety and effectiveness of this drug combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/09/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Lung Cancer
Hepatic Arterial Infusion (HAI) of Abraxane
Completed
The goal of this clinical research study is find the highest tolerated dose of Abraxane (nab-paclitaxel) that can be given directly into the liver of patients with advanced cancer that has spread to the liver.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/04/2016
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Liver Cancer, Advanced Cancers, Solid Tumors
Genasense, Carboplatin, Paclitaxel (GCP) Combination in Uveal Melanoma
Terminated
The goal of this clinical research is to learn if the combination of Genasense (oblimersen), carboplatin, and paclitaxel (GCP) can help to control metastatic uveal melanoma. The safety of this combination will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/13/2016
Locations: UT MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma
Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer
Completed
The purpose of this study is to evaluate the efficacy and safety of treatment with imetelstat + paclitaxel (with or without bevacizumab) versus paclitaxel (with or without bevacizumab) alone for patients with locally recurrent or metastatic breast cancer who have not received chemotherapy or have received one non-taxane based chemotherapy for metastatic breast cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/22/2015
Locations: Scott & White Healthcare, Temple, Texas
Conditions: Locally Recurrent or Metastatic Breast Cancer
A Study of MM-111 in Combination With Multiple Treatments in Patients With HER2 Positive Cancer
Completed
This study is an open-label, dose-escalation study of MM-111 with five different combination treatments with the main goal of determining the safety of MM-111 with each combination.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/15/2015
Locations: Texas Oncology Cancer Center, Austin, Texas +2 locations
Conditions: HER-2 Gene Amplification
Hepatic Arterial Infusion of Nab-Paclitaxel in Patients With Metastatic Melanoma in the Liver
Completed
The goal of this clinical research is to find the highest tolerable dose of Abraxane (nab-paclitaxel) when given directly to the area where the cancer is located. The safety of this drug will also be studied.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/25/2015
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Melanoma, Liver Metastasis
Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer
Completed
Phase I: will look at different dose levels and regimens of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.
Phase II: will assess the efficacy and safety of the 10mg daily dose of everolimus combined with weekly trastuzumab and paclitaxel therapy in patients with HER-2 overexpressing metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
11/24/2015
Locations: Sammons Cancer Center - Texas Oncology, Dallas, Texas
Conditions: Metastatic Breast Cancer
625 - 636 of 768